MX2017005672A - Erradicacion guiada de arn de virus jc mano y otros poliomavirus. - Google Patents
Erradicacion guiada de arn de virus jc mano y otros poliomavirus.Info
- Publication number
- MX2017005672A MX2017005672A MX2017005672A MX2017005672A MX2017005672A MX 2017005672 A MX2017005672 A MX 2017005672A MX 2017005672 A MX2017005672 A MX 2017005672A MX 2017005672 A MX2017005672 A MX 2017005672A MX 2017005672 A MX2017005672 A MX 2017005672A
- Authority
- MX
- Mexico
- Prior art keywords
- polyomaviruses
- virus
- eradication
- man
- rna guided
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención incluye métodos y composiciones para la eliminación de poliomavirus, tales como Virus John Cunningham (JVC), de células huésped, y el tratamiento de enfermedades relacionadas con poiliomavirus, tales como leucoencefalopatía multifocal progresiva (PML). Las composiciones incluyen secuencias de ácido nucleico aislado que comprenden una endonucleasa asociada con CRISPR y un ARN de guía, en donde el ARN de guía es complementario a una secuencia objetivo en un poliomavirus.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072927P | 2014-10-30 | 2014-10-30 | |
US201562169390P | 2015-06-01 | 2015-06-01 | |
US201562169638P | 2015-06-02 | 2015-06-02 | |
PCT/US2015/058351 WO2016070070A1 (en) | 2014-10-30 | 2015-10-30 | Rna guided eradication of human jc virus and other polyomaviruses |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005672A true MX2017005672A (es) | 2018-11-09 |
Family
ID=55858408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005672A MX2017005672A (es) | 2014-10-30 | 2015-10-30 | Erradicacion guiada de arn de virus jc mano y otros poliomavirus. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20170333572A1 (es) |
EP (1) | EP3212795A4 (es) |
CN (2) | CN107406854B (es) |
AU (1) | AU2015338993B2 (es) |
CA (1) | CA2967990C (es) |
HK (1) | HK1247636A1 (es) |
MA (1) | MA40880A (es) |
MX (1) | MX2017005672A (es) |
RU (1) | RU2747722C2 (es) |
WO (1) | WO2016070070A1 (es) |
ZA (1) | ZA201703163B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012333134B2 (en) | 2011-07-22 | 2017-05-25 | John Paul Guilinger | Evaluation and improvement of nuclease cleavage specificity |
EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
CN108473527A (zh) * | 2015-12-09 | 2018-08-31 | 切除生物治疗公司 | 用于消除免疫抑制疗法期间jc病毒激活和pml(进行性多灶性白质脑病)风险的基因编辑方法和组合物 |
US20190038770A1 (en) * | 2016-01-25 | 2019-02-07 | Excision Biotherapeutics,Inc. | Rna guided eradication of human jc virus and other polyomaviruses |
US20190161743A1 (en) * | 2016-05-09 | 2019-05-30 | President And Fellows Of Harvard College | Self-Targeting Guide RNAs in CRISPR System |
US20200095586A1 (en) * | 2016-06-01 | 2020-03-26 | Excision Biotherapeutics, Inc. | Compositions and methods of treatment for lytic and lysogenic viruses |
EP3487523B1 (en) * | 2016-07-19 | 2023-09-06 | Duke University | Therapeutic applications of cpf1-based genome editing |
CA3032699A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
KR102687373B1 (ko) | 2017-03-23 | 2024-07-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
WO2020191249A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
EP4058050A4 (en) * | 2019-11-11 | 2023-11-29 | Temple University of the Commonwealth System of Higher Education | CRISPR/CAS9 SYSTEM AS AN AGENT FOR INHIBITING JC POLYOMA INFECTION |
MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
CN112322587A (zh) * | 2020-09-17 | 2021-02-05 | 杭州市第一人民医院 | 一种带Cas9基因的人源可诱导多能干细胞系、构建方法、鉴定方法及应用 |
RU2747820C1 (ru) * | 2020-11-30 | 2021-05-14 | Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) | Система CRISPR-Cas для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях |
RU2747819C1 (ru) * | 2020-11-30 | 2021-05-14 | Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) | Способ получения препарата рибонуклеопротеинового комплекса CRISPR/Cas и препарат для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
JP4812874B2 (ja) * | 2006-04-28 | 2011-11-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Jcウイルス遺伝子の発現を抑制するための組成物および方法 |
WO2014113493A1 (en) * | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
-
2015
- 2015-10-29 MA MA040880A patent/MA40880A/fr unknown
- 2015-10-30 CN CN201580068318.6A patent/CN107406854B/zh active Active
- 2015-10-30 WO PCT/US2015/058351 patent/WO2016070070A1/en active Application Filing
- 2015-10-30 US US15/523,272 patent/US20170333572A1/en not_active Abandoned
- 2015-10-30 AU AU2015338993A patent/AU2015338993B2/en active Active
- 2015-10-30 CA CA2967990A patent/CA2967990C/en active Active
- 2015-10-30 RU RU2017115838A patent/RU2747722C2/ru active
- 2015-10-30 EP EP15855311.5A patent/EP3212795A4/en active Pending
- 2015-10-30 CN CN202210155200.9A patent/CN115044570A/zh active Pending
- 2015-10-30 MX MX2017005672A patent/MX2017005672A/es unknown
-
2017
- 2017-05-08 ZA ZA2017/03163A patent/ZA201703163B/en unknown
-
2018
- 2018-05-25 HK HK18106893.5A patent/HK1247636A1/zh unknown
-
2022
- 2022-04-22 US US17/727,438 patent/US20230001016A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170333572A1 (en) | 2017-11-23 |
US20230001016A1 (en) | 2023-01-05 |
ZA201703163B (en) | 2019-03-27 |
MA40880A (fr) | 2017-09-05 |
CN107406854B (zh) | 2022-03-11 |
EP3212795A1 (en) | 2017-09-06 |
AU2015338993B2 (en) | 2021-12-09 |
CA2967990C (en) | 2024-02-13 |
RU2017115838A3 (es) | 2018-11-30 |
RU2747722C2 (ru) | 2021-05-13 |
RU2017115838A (ru) | 2018-11-30 |
CN107406854A (zh) | 2017-11-28 |
EP3212795A4 (en) | 2018-06-27 |
WO2016070070A1 (en) | 2016-05-06 |
CA2967990A1 (en) | 2016-05-06 |
HK1247636A1 (zh) | 2018-09-28 |
AU2015338993A1 (en) | 2017-05-25 |
CN115044570A (zh) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017005672A (es) | Erradicacion guiada de arn de virus jc mano y otros poliomavirus. | |
MX2016002586A (es) | Métodos y composiciones para el tratamiento guiado por rna de infección por hiv. | |
SA519401379B1 (ar) | علاج فيروس مرتبط بغدة لمرض هنتنجتون | |
MX2016011686A (es) | Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc). | |
PT3216867T (pt) | Método para modificar a sequência de genoma para introduzir mutação específica a sequência de adn alvo por reação de remoção de bases, e complexo molecular nele utilizado | |
MX2022002624A (es) | Edicion del genoma sin nucleasas. | |
WO2015112896A3 (en) | Methods and compositions for sequences guiding cas9 targeting | |
NZ727481A (en) | Methods and compositions for modifying a targeted locus | |
EA201890012A1 (ru) | Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич | |
MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
MX2016013034A (es) | Composicion detergente. | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
EA201491539A1 (ru) | Улучшение засухоустойчивости у растений: пектинэстераза | |
PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
MD4733B1 (ro) | Anticorpi anti-TIGIT | |
EA201791768A1 (ru) | Иммуномодулирующие агенты | |
EA201691581A1 (ru) | Способы и композиции для повышения эффективности направленной модификации генов с применением опосредованной олигонуклеотидами репарации генов | |
SG10201805815YA (en) | Rna-guided gene drives | |
MX2018010483A (es) | Inmunogenos para vacunacion contra vih. | |
MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
MX2016008518A (es) | Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo. | |
IN2015DN04148A (es) | ||
MX2016010100A (es) | Secuenciacion libre de error de acido desoxirribonucleico (adn). | |
WO2015032800A3 (en) | Compositions and methods for inducing senescence in cancer cells | |
PH12017502389A1 (en) | Jasmonic acid pathway activator |